
Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer
pharmafile | August 1, 2019 | News story | Research and Development | Cancer, Kisqali, Novartis, breast cancer, pharma
New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in the first- and second-line treatment of hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women.
The findings showed that the combo “achieved statistically significant improvement in overall survival”, building on previous trial results that showed its benefit in prolonging life in patients. No additional safety signals were discovered.
“We are thrilled that Kisqali combination therapy again has demonstrated improved overall survival for patients with HR+/HER2- advanced breast cancer – first in pre-menopausal and peri-menopausal women in MONALEESA-7, and now in post-menopausal women in MONALEESA-3,” said Dr Susanne Schaffert, President, Novartis Oncology. “We will continue to reimagine cancer to help patients live longer, and also improve quality of life as we work towards finding a cure for this incurable disease.”
Novartis intends to reveal the full results at an upcoming medical congress, as well as submit them to global health authorities.
Matt Fellows
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Micrima announces upcoming launch of new UK breast cancer assessment
Breast cancer remains one of the leading health threats to women over 35 in the …

Pierre Fabre partners with Know Your Lemons Foundation for breast cancer awareness
The campaign focuses on early detection and education Pierre Fabre Laboratories has announced a partnership …






